Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 31, 2026
Subject: Announcement of headline results from the ZEUS phase 3 cardiovascular outcomes trial for the investigational drug ziltivekimab.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. It focuses on clinical trial outcomes and their financial implications.
- Financial Impact: The outcome will result in a non-cash impairment charge in Q3 2026.
- Outlook Impact: The outcome will not impact the previously communicated adjusted operating profit outlook for 2026.
Material Changes and Clinical Results
The primary material change is the failure of the ZEUS trial to meet its primary endpoint.
- Trial Outcome: Ziltivekimab did not demonstrate a reduction in Major Adverse Cardiovascular Events (MACE) versus placebo (Hazard Ratio: 0.99; 95% CI: 0.88 to 1.11).
- Biological Effect: The drug successfully inhibited the IL-6 pathway, reducing free IL-6 and hsCRP, but this did not translate to clinical cardiovascular benefits in the studied population (ASCVD, CKD, and inflammation).
- Safety Profile: Overall adverse events were similar to placebo. A higher proportion of serious infections was observed in the ziltivekimab group, consistent with IL-6 inhibition. No difference in all-cause mortality was observed.
Guidance, Outlook, and Risks
Management Commentary: Martin Holst Lange, Chief Scientific Officer, stated that while the MACE benefit was not achieved, the company remains strategically committed to cardiovascular disease research. The data will inform ongoing development.
Future Trials: Two additional cardiovascular outcomes trials for ziltivekimab are continuing:
- HERMES: Investigating heart failure.
- ARTEMIS: Investigating patients following an acute heart attack.
- Timeline: Both are anticipated to read out in the first half of 2027.
Risks and Contingencies: The filing highlights the risk of clinical trial failure leading to asset impairment. The specific value of the impairment charge is not disclosed in this text.
Investor Verification Checklist
- Verify the specific monetary value of the non-cash impairment charge to be recorded in Q3 2026.
- Confirm the detailed safety data regarding serious infections in the ZEUS trial.
- Monitor the progress and interim data of the ongoing HERMES and ARTEMIS trials scheduled for 2027 readout.
- Review the full scientific presentation of ZEUS results at the upcoming 2026 scientific meeting.